July 13, 2016
AnGes MG said on July 12 that it has completed the development of a platform technology for its nucleic acid medicine, chimera decoy oligonucleotides, that simultaneously inhibit multiple targets. The company intends to develop anti-inflammatory treatments, using the chimera decoy...read more